Niemoeller E, et al. - The experts undertook this study to examine whether insulin glargine U100 (iGlar) + lixisenatide (iGlarLixi) reduced glycated hemoglobin (HbA_1c) to a greater extent compared to basal insulin, regardless of levels at screening. Without increasing the risk of hypoglycemia, iGlarLixi controlled HbA_1c levels more effectively compared to iGlar across all HbA_1c screening subgroups and in the overall study population.